Lv5
1450 积分 2022-09-12 加入
Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis
1个月前
已完结
Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles
1个月前
已完结
Pan-cancer single-cell landscape of tumor-infiltrating T cells
2个月前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
3个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
3个月前
已完结
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
3个月前
已完结
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
3个月前
已完结
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
3个月前
已完结
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
3个月前
已完结
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
3个月前
已完结
皖公网安备34019202002308
